Methamphetamine-Associated Psychosis (MAP) – The Clinical Spectrum
Recent years have seen a dramatic increase in the use of the synthetic stimulant, methamphetamine, particularly in its crystalline form.
Advances in methamphetamine processing have resulted in a drug that now has a higher average purity (increased from 21% to 64%) and therefore a higher potency.
This increase in purity and potency has resulted in an increased price ($464 to $795 per gram) however the average purity-adjusted price per gram has declined. 
Taken together, these increases in purity and potency as well as its favourable pricing, is challenging people’s control of methamphetamine consumption.
- Clinical features including delusions and cognitive impairment
- Increased psychological distress and higher rates of depression and anxiety
- Methamphetamine-associated psychosis (MAP) resulting from chronic use
We covered the assessment and management of methamphetamine addiction in a previous article. This article focuses on the methamphetamine associated psychotic symptoms and the differences from a primary psychotic illness.